Search

Sodium carbonate

Sodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. … As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.

Cipaglucosidase alfa

Cipaglucosidase alfa is conjugated with mannose-6-phosphate (M6P) N-glycans that bind to the cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, one of the main affected tissues … in Pompe disease.

Poliovirus type 3 antigen (formaldehyde inactivated)

The vaccine contains purified and inactivated poliovirus type 3 that were grown from a continuous line of monkey kidney cells. … Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

Sodium molybdate

Dibotermin alfa

Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … It is implanted in patients undergoing bone surgeries or those with fractures.

Aliskiren

Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. … [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.

Poliovirus type 2 antigen (formaldehyde inactivated)

The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells. … Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

Betamethasone phosphate

[L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994] … Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible [betamethasone] to agonize glucocorticoid receptors.

Linvoseltamab

FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the